menu
    • menu

    Company profile for Glenmark Pharmaceuticals

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 65 countries including the US, various countries in the EU, South...
    Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 65 countries including the US, various countries in the EU, South America and India. With 15 manufacturing facilities and 3 R&D centers dedicated to the goal of enriching lives across the globe.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Glenmark Pharmaceuticalsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andhe...
    Telephone
    Telephone
    +91 22 4018 9999
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glenmarkpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 4785

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    The year 2024 was marked by some landmark drug approvals in the areas of schizophrenia, metabolic dysfunction-associated steatohepatitis (MASH), chronic obstructive pulmonary disease (COPD) and Alzheimer’s disease. The incoming Trump administration, monkeypox outbreak and drug price negotiations in the US also created big news. Here is PharmaCompass’ compilation of the top 10 news from Phispers of 2024. I. BMS’ US$ 14 bn Karuna bet pays off with landmark FDA approval for schizophrenia med Cobenfy The US Food and Drug Administration’s groundbreaking approval of Bristol Myers Squibb’s Cobenfy to treat schizophrenia has made it to our number one spot. BMS had acquired Cobenfy through its US$ 14 billion purchase of Karuna Therapeutics, announced in December 2023. Cobenfy is the first-ever antipsychotic that targets cholinergic receptors. Cobenfy’s new approach has experts excited. Its peak sales are expected to come in at US$ 7.5 billion a year. While BMS’ Karuna buyout paid off, AbbVie’s US$ 8.7 billion acquisition of Cerevel Therapeutics was dampened when their lead candidate and schizophrenia drug emraclidine failed to meet phase 2 endpoints in two pivotal trials. II. 2024’s biggest deal, US$ 16.5 bn Catalent buyout by Novo’s parent, cleared after intense scrutiny  On number two spot is Novo Nordisk Foundation’s acquistion of Catalent via its investment arm Novo Holdings for US$ 16.5 billion, announced in February 2024. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. Easily the biggest biopharma acquisition of last year, the deal  faced criticism from lawmakers and consumer groups for its potential anti-competitive effects, particularly in the glucagon-like peptide-1 (GLP-1) drug market. Its main competitor Eli Lilly called for scrutiny by competition regulators. However, in December, both the EU regulator and the US Federal Trade Commission gave it the greenlight. III. Madrigal’s Rezdiffra becomes first FDA-approved drug for liver disease MASH For quite some time, the drug development field for the liver condition MASH had been a graveyard for failed programs. In 2024, the field celebrated a hurrah moment when Madrigal’s oral drug Rezdiffra became the first treatment in the US for adults with this common fatty liver disease. The approval has opened a multi-billion dollar opportunity for Madrigal with the American Liver Foundation CEO Lorraine Stiehl calling it a “game-changing” moment. IV. COPD patients get two new treatments — Verona’s Ohtuvayre and Sanofi-Regeneron’s Dupixent The COPD landscape saw remarkable advances in 2024. FDA approved Verona Pharma’s Ohtuvayre, which brings the first new mechanism of action in over two decades for the treatment of COPD. This dual-action, inhaled medication serves as both a bronchodilator and an anti-inflammatory agent, offering a comprehensive approach to symptom management. Adding to this progress, Sanofi and Regeneron’s Dupixent achieved a historic milestone by becoming the first biologic approved for treating COPD. Over 390 million people are living with COPD worldwide. V. Novartis inks 20 deals in 2024, promises over US$ 25 billion in biobucks, lays bets on radiopharmas Novartis has been investing in early-stage science, buying out companies in the sub-US$ 5 billion range. The Swiss drugmaker Novartis inked over 20 deals in 2024, paying over US$ 5.5 billion upfront and promising over US$ 25 billion in biobucks. The company has particularly focused on radiopharmaceuticals and molecular glue degraders. It acquired Mariana Oncology to strengthen its radioligand therapy (RLT) pipeline, and also inked RLT deals with PeptiDream and Ratio Therapeutics. VI. Despite political pressure, FDA rejects first MDMA-assisted therapy to treat PTSD; Lykos faces expanded probe In August, FDA declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat post-traumatic stress disorder (PTSD). In the lead-up to the FDA decision, 80 members of Congress from both sides of the aisle had urged US President Joe Biden and the FDA to consider further studies on the therapy. Not satisfied with just declining Lykos’ MDMA-assisted therapy for PTSD, FDA had expanded its investigation into the clinical trials that tested it. Lykos CEO Amy Emerson stepped down after reducing its workforce by 75 percent. Additionally, its founder Rick Doblin exited its board. VII. Alzheimer’s gets two new treatments as FDA approves Lilly’s Kisunla, Alpha Cognition’s Zunveyl FDA finally approved Eli Lilly’s Alzheimer’s drug Kisunla in July, after delaying action on it in March. This approval, along with that of Biogen and Eisai’s Leqembi in 2023, mark successes in treating the mind-wasting disease after three decades of failed efforts. FDA also approved Alpha Cognition’s Zunveyl to treat mild-to-moderate Alzheimer’s disease. Zunveyl is a prodrug of Alzheimer’s medication galantamine, and is to be taken orally twice a day. Alpha said Zunveyl is designed to address the tolerability issues with galantamine. VIII. IRA price talks conclude; Stelara, Enbrel, Eliquis to bring 51.4% of Medicare savings After filing futile lawsuits questioning the constitutional validity of the Medicare drug price negotiations under the Inflation Reduction Act (IRA), all drug companies came to the bargaining table. In August, the Biden-Harris Administration announced it had reached agreements for lower prices for all 10 drugs selected for negotiations under the IRA. The new prices come into effect from January 1, 2026. A Brookings Institution report said that just three drugs will account for over half of the expected US$ 6 billion savings in 2026. J&J’s Stelara (US$ 1.4 billion), Amgen’s Enbrel (US$ 1.1 billion), and BMS’ Eliquis (US$ 856 million) are expected to account for US$ 3.28 billion or 51.4 percent of Medicare savings. IX. Trump’s picks for new administration send shockwaves across markets, stocks of vaccine makers tumble  Donald Trump’s picks for his new administration not only created big news, but also impacted the stock markets. His selection of Robert F. Kennedy Jr., an anti-vaccine activist, to lead the Department of Health and Human Services (HHS), sent shares of several vaccine manufacturers plummeting. In the US, stocks of Pfizer, Moderna, and Novavax dipped. In Europe, stocks of BioNTech, GSK, and Bavarian Nordic tumbled. Trump has nominated Mehmet Oz, a celebrity TV host, to run the Centers for Medicare and Medicaid Services (CMS), which oversees health insurance. X. New mpox outbreak in Africa sparks global response; FDA approves Emergent’s vaccine to treat mpox In August, a new mpox virus clade put Africa in the throes of an mpox outbreak. The WHO declared it a public health emergency of international concern. Emergent BioSolutions said it will donate 50,000 doses of its smallpox vaccine ACAM2000. Multiple countries responded with donations of Bavarian Nordic’s Jynneos, the only widely-approved mpox vaccine at the time. In early September, the FDA approved Emergent’s ACAM2000 as the second mpox vaccine.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1046

    https://www.pharmacompass.com/radio-compass-blog/fda-s-landmark-approvals-of-bms-schizo-med-madrigal-s-mash-drug-us-16-5-bn-catalent-buyout-make-it-to-top-10-news-of-2024

    #Phispers by PHARMACOMPASS
    02 Jan 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of January 1, 2025
    Enforcement Report - Week of January 1, 2025

    01 Jan 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-1-2025-88420.pdf

    FDA
    01 Jan 2025
    Share Share
    Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL
    Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

    18 Dec 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/glenmark-usa-launches-lacosamide-oral-solution-10-mgml-16542

    INDPHARMAPOST
    18 Dec 2024
    Share Share
    Glenmark Pharma arm launches seizure drug in US
    Glenmark Pharma arm launches seizure drug in US

    16 Dec 2024

    // BUSSINESS STD

    https://www.business-standard.com/markets/capital-market-news/glenmark-pharma-arm-launches-seizure-drug-in-us-124121600227_1.html

    BUSSINESS STD
    16 Dec 2024
    Share Share
    Glenmark Pharma Shares Up 2% on Rolling Out Lacosamide Solution
    Glenmark Pharma Shares Up 2% on Rolling Out Lacosamide Solution

    16 Dec 2024

    // BUSINESS STD

    https://www.business-standard.com/markets/news/glenmark-pharma-share-price-up-2-on-rolling-out-lacosamide-oral-solution-124121600332_1.html

    BUSINESS STD
    16 Dec 2024
    Share Share
    Aurobindo, Glenmark, Zydus Recall Products in US Over Manufacturing
    Aurobindo, Glenmark, Zydus Recall Products in US Over Manufacturing

    15 Dec 2024

    // BUSINESS STD

    https://www.business-standard.com/industry/news/aurobindo-pharma-glenmark-and-zydus-recall-products-in-us-over-mfg-issues-124121500207_1.html

    BUSINESS STD
    15 Dec 2024
    Share Share
    Enforcement Report - Week of December 11, 2024
    Enforcement Report - Week of December 11, 2024

    11 Dec 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-11-2024-90405.pdf

    FDA
    11 Dec 2024
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Glenmark Pharmaceuticals Limited and get a quotation

    Glenmark Pharmaceuticals Limited is a supplier offers 118 products (APIs, Excipients or Intermediates).

    Find a price of Alfuzosin HCl bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Fluconazole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Palonosetron bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Simvastatin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Tadalafil bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Telmisartan bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of MFG SITE FACILITIES OPERATING PROCEDURES AND PERSONEL FOR SATPUR NASIK INDIA SITE bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Adapalene bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Alogliptin Benzoate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Amiodarone Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Apixaban bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Apremilast bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Aprepitant bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Arformoterol Tartrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Atomoxetin Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Atovaquone bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Azelaic Acid bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Azelnidipine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Azilsartan bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Bilastine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Bosentan Hydrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Brivaracetam bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Bupropion Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Butenafine Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Canagliflozin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Cilazapril bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Cilostazol bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Colesevelam Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Colistimethate Sodium bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Dabigatran Etexilate Mesylate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Dapagliflozin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Deferasirox bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Deoxycholic Acid bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Desloratadine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Dimethyl Fumarate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Dipyridamole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Diroximel fumarate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Dronedarone Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Edoxaban Tosylate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Efinaconazole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Elagolix Sodium bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Empagliflozin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Eslicarbazepine Acetate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Esomeprazole Magnesium bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Esomeprazole Sodium bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Eszopiclone bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Etoricoxib bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Ezetimibe bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Favipiravir bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Fingolimod Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Fosaprepitant bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Frovatriptan bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Gabapentin Enacarbil bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Garenoxacin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Glimepiride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Imiquimod bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Iron Sucrose bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Ivacaftor bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Labetalol Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lacosamide bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lasmiditan bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lercanidipine HCl bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Levocetirizine Dihydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lifitegrast bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Linagliptin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lithium Carbonate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lomitapide bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lornoxicam bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Luliconazole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Lurasidone Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Milnacipran HCl bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Mirabegron bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Moexipril bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Nebivolol bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Nintedanib Esylate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Olmesartan Medoxomil bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Olopatadine Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Omeprazole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Oxcarbazepine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Patiromer bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Perindopril Arginine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Perindopril Erbumine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Pirfenidone bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Prasugrel bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Proguanil bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Ranolazine bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rasagiline Mesylate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rasagiline Tartrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Riluzole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rivaroxaban bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rizatriptan Benzoate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Roflumilast bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Ropinirole Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rosuvastatin Calcium bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Rufinamide bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Saxagliptin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Sertaconazole Nitrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Solifenacin Succinate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Solriamfetol Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Sucralfate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Tafamidis bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Tavaborole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Teneligliptin Hydrobromide bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Terbinafine Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Teriflunomide bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Ticagrelor bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Tofacitinib Citrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Topiramate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Trandolapril bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Trospium Chloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Umifenovir bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Verapamil bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Vilazodone Hydrochloride bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Vildagliptin bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Voriconazole bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Zolmitriptan bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Zolpidem Tartrate bulk offered by Glenmark Pharmaceuticals Limited

    Find a price of Zonisamide bulk offered by Glenmark Pharmaceuticals Limited

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search